miRNA Details
miRNA General Information | |||||
---|---|---|---|---|---|
miRNA Mature ID | hsa-miR-20a-5p | ||||
miRNA Stemloop AC | MI0000076 | ||||
miRNA Stemloop ID | hsa-mir-20a | ||||
Sequence | uaaagugcuuauagugcagguag | ||||
TTD Target(s) Regulated by This miRNA | Tyrosine-protein kinase Kit (KIT) | Successful Target | Target Info | [1] | |
Peroxisome proliferator-activated receptor gamma (PPAR-gamma) | Successful Target | Target Info | [2] | ||
Amyloid beta A4 protein (APP) | Successful Target | Target Info | [3] | ||
Apoptosis regulator Bcl-2 (BCL-2) | Successful Target | Target Info | [4] | ||
Janus kinase 1 (JAK-1) | Successful Target | Target Info | [5] | ||
Signal transducer and activator of transcription 3 (STAT3) | Successful Target | Target Info | [6] | ||
Vascular endothelial growth factor A (VEGFA) | Successful Target | Target Info | [7] | ||
TGF-beta receptor type I (TGFBR1) | Clinical trial Target | Target Info | [8] | ||
Wee1-like protein kinase (WEE1) | Clinical trial Target | Target Info | [9] | ||
Cellular tumor antigen p53 (TP53) | Clinical trial Target | Target Info | [10] | ||
DNA [cytosine-5]-methyltransferase 1 (DNMT1) | Clinical trial Target | Target Info | [11] | ||
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) | Clinical trial Target | Target Info | [12] | ||
Apoptosis signal-regulating kinase 1 (MAP3K5) | Clinical trial Target | Target Info | [13] | ||
G1/S-specific cyclin-D1 (CCND1) | Clinical trial Target | Target Info | [14] | ||
GTPase NRas (NRAS) | Clinical trial Target | Target Info | [3] | ||
TGF-beta receptor type II (TGFBR2) | Clinical trial Target | Target Info | [15] | ||
Gap junction alpha-1 protein (GJA1) | Clinical trial Target | Target Info | [16] | ||
Hypoxia-inducible factor 1 alpha (HIF-1A) | Clinical trial Target | Target Info | [17] | ||
Tumor susceptibility gene protein 101 (TSG101) | Clinical trial Target | Target Info | [18] | ||
E2F transcription factor 1 (E2F1) | Clinical trial Target | Target Info | [19] | ||
Hypoxia-inducible factor 2 alpha (HIF-2A) | Successful Target | Target Info | [20] | ||
Thrombospondin-1 (THBS1) | Clinical trial Target | Target Info | [21] | ||
Stress-activated protein kinase JNK2 (JNK2) | Preclinical Target | Target Info | [9] | ||
Bone morphogenetic protein receptor (BMPR2) | Literature-reported Target | Target Info | [22] | ||
Phosphatase and tensin homolog (PTEN) | Literature-reported Target | Target Info | [23] | ||
Proto-oncogene c-Myc (MYC) | Literature-reported Target | Target Info | [24] | ||
Death-associated protein kinase 3 (DAPK3) | Literature-reported Target | Target Info | [25] | ||
LIM domain kinase-1 (LIMK-1) | Literature-reported Target | Target Info | [26] | ||
Protein kinase G1 (PRKG1) | Literature-reported Target | Target Info | [27] | ||
Tyrosine-protein kinase ABL2 (ABL2) | Literature-reported Target | Target Info | [28] | ||
Integrin beta-8 (ITGB8) | Clinical trial Target | Target Info | [29] | ||
Kinesin-like protein KIF26B (KIF26B) | Literature-reported Target | Target Info | [30] | ||
Melanoma differentiation-associated protein 6 (CDKN1A) | Literature-reported Target | Target Info | [31] | ||
Runt-related transcription factor 3 (RUNX3) | Literature-reported Target | Target Info | [32] | ||
Protein(s) Regulated by This miRNA | Autophagy-related protein 16-1 | Regulated Protein | [33] | ||
Bcl-2-like protein 11 | Regulated Protein | [34] | |||
BCL2/adenovirus E1B 19 kDa protein-interacting protein 2 | Regulated Protein | [35] | |||
BMP and activin membrane-bound inhibitor homolog | Regulated Protein | [2] | |||
Cysteine-rich motor neuron 1 protein | Regulated Protein | [2] | |||
Dual specificity mitogen-activated protein kinase kinase 3 | Regulated Protein | [37] | |||
Dual specificity protein phosphatase 2 | Regulated Protein | [38] | |||
E3 SUMO-protein ligase EGR2 | Regulated Protein | [39] | |||
Egl nine homolog 3 | Regulated Protein | [40] | |||
ETS translocation variant 1 | Regulated Protein | [41] | |||
F-box only protein 31 | Regulated Protein | [42] | |||
G1/S-specific cyclin-D2 | Regulated Protein | [9] | |||
Homeobox protein PKNOX1 | Regulated Protein | [44] | |||
Interferon regulatory factor 2 | Regulated Protein | [1] | |||
Metalloproteinase inhibitor 2 | Regulated Protein | [46] | |||
Mitogen-activated protein kinase kinase kinase 12 | Regulated Protein | [47] | |||
Mothers against decapentaplegic homolog 4 | Regulated Protein | [48] | |||
Mucin-17 | Regulated Protein | [49] | |||
Myocyte-specific enhancer factor 2D | Regulated Protein | [47] | |||
Netrin-4 | Regulated Protein | [50] | |||
NF-kappa-B inhibitor beta | Regulated Protein | [51] | |||
PH domain leucine-rich repeat-containing protein phosphatase 2 | Regulated Protein | [52] | |||
Polycystin-1 | Regulated Protein | [53] | |||
Progressive ankylosis protein homolog | Regulated Protein | [54] | |||
RB1-inducible coiled-coil protein 1 | Regulated Protein | [55] | |||
RE1-silencing transcription factor | Regulated Protein | [56] | |||
Receptor-type tyrosine-protein phosphatase O | Regulated Protein | [57] | |||
Regulator of G-protein signaling 5 | Regulated Protein | [58] | |||
Retinoblastoma-associated protein | Regulated Protein | [9] | |||
Retinoblastoma-like protein 1 | Regulated Protein | [9] | |||
Retinoblastoma-like protein 2 | Regulated Protein | [9] | |||
Rho GTPase-activating protein 12 | Regulated Protein | [59] | |||
Runt-related transcription factor 1 | Regulated Protein | [60] | |||
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform | Regulated Protein | [57] | |||
Transcription elongation factor A protein-like 1 | Regulated Protein | [6] | |||
Transcriptional activator protein Pur-alpha | Regulated Protein | [62] | |||
Transmembrane gamma-carboxyglutamic acid protein 1 | Regulated Protein | [50] | |||
Tumor protein p53-inducible nuclear protein 1 | Regulated Protein | [63] | |||
Tyrosine-protein phosphatase non-receptor type substrate 1 | Regulated Protein | [64] | |||
Ubiquitin-conjugating enzyme E2 C | Regulated Protein | [65] | |||
Zinc finger FYVE domain-containing protein 9 | Regulated Protein | [66] | |||
References | |||||
REF 1 | Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia. Haematologica. 2011 Dec;96(12):1783-91. | ||||
REF 2 | MiRNA-20a promotes osteogenic differentiation of human mesenchymal stem cells by co-regulating BMP signaling. RNA Biol. 2011 Sep-Oct;8(5):829-38. | ||||
REF 3 | MicroRNA regulation of Alzheimer's Amyloid precursor protein expression. Neurobiol Dis. 2009 Mar;33(3):422-8. | ||||
REF 4 | miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9. | ||||
REF 5 | Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood. 2010 Jun 10;115(23):4944-50. | ||||
REF 6 | HIF-1 downregulates miR-17/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation. Cell Death Differ. 2013 Mar;20(3):408-18. | ||||
REF 7 | The effect of central loops in miRNA:MRE duplexes on the efficiency of miRNA-mediated gene regulation. PLoS One. 2008 Mar 5;3(3):e1719. | ||||
REF 8 | FGF2 inhibits endothelial-mesenchymal transition through microRNA-20a-mediated repression of canonical TGF- signaling. J Cell Sci. 2016 Feb 1;129(3):569-79. | ||||
REF 9 | MicroRNAs MiR-17, MiR-20a, and MiR-106b act in concert to modulate E2F activity on cell cycle arrest during neuronal lineage differentiation of USSC. PLoS One. 2011 Jan 20;6(1):e16138. | ||||
REF 10 | Upregulation of the miR-17-92 cluster and its two paraloga in osteosarcoma - reasons and consequences. Genes Cancer. 2014 Apr;5(1-2):56-63. | ||||
REF 11 | Epigenetic regulation of miR-17~92 contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med. 2013 Feb 15;187(4):397-405. | ||||
REF 12 | Decrease expression of microRNA-20a promotes cancer cell proliferation and predicts poor survival of hepatocellular carcinoma. J Exp Clin Cancer Res. 2013 Apr 18;32(1):21. | ||||
REF 13 | MiR-20a regulates ASK1 expression and TLR4-dependent cytokine release in rheumatoid fibroblast-like synoviocytes. Ann Rheum Dis. 2013 Jun;72(6):1071-9. | ||||
REF 14 | MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res. 2008 May;18(5):549-57. | ||||
REF 15 | In-depth analysis of the interaction of HIV-1 with cellular microRNA biogenesis and effector mechanisms. MBio. 2013 Apr 16;4(2):e000193. | ||||
REF 16 | Suppression of CX43 expression by miR-20a in the progression of human prostate cancer. Cancer Biol Ther. 2012 Aug;13(10):890-8. | ||||
REF 17 | Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster. Cancer Res. 2008 Jul 15;68(14):5540-5. | ||||
REF 18 | A quantitative analysis of CLIP methods for identifying binding sites of RNA-binding proteins. Nat Methods. 2011 May 15;8(7):559-64. | ||||
REF 19 | c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005 Jun 9;435(7043):839-43. | ||||
REF 20 | MicroRNA-17, 20a regulates the proangiogenic function of tumor-associated macrophages via targeting hypoxia-inducible factor 2. PLoS One. 2013 Oct 23;8(10):e77890. | ||||
REF 21 | The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Res. 2010 Oct 15;70(20):8233-46. | ||||
REF 22 | Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res. 2009 May 22;104(10):1184-91. | ||||
REF 23 | miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 2009 Dec 15;23(24):2839-49. | ||||
REF 24 | A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol. 2008 Aug 11;182(3):509-17. | ||||
REF 25 | Oncogenic miR-17/20a Forms a Positive Feed-forward Loop with the p53 Kinase DAPK3 to Promote Tumorigenesis. J Biol Chem. 2015 Aug 7;290(32):19967-75. | ||||
REF 26 | MiR-20a is upregulated in anaplastic thyroid cancer and targets LIMK1. PLoS One. 2014 May 23;9(5):e96103. | ||||
REF 27 | MiR-20a regulates the PRKG1 gene by targeting its coding region in pulmonary arterial smooth muscle cells. FEBS Lett. 2014 Dec 20;588(24):4677-85. | ||||
REF 28 | miR-20a promotes prostate cancer invasion and migration through targeting ABL2. J Cell Biochem. 2014 Jul;115(7):1269-76. | ||||
REF 29 | MicroRNA-17/20a functions to inhibit cell migration and can be used a prognostic marker in oral squamous cell carcinoma. Oral Oncol. 2013 Sep;49(9):923-931. | ||||
REF 30 | MiR-20a-5p represses multi-drug resistance in osteosarcoma by targeting the KIF26B gene. Cancer Cell Int. 2016 Aug 5;16:64. | ||||
REF 31 | MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood. 2009 Jan 8;113(2):396-402. | ||||
REF 32 | Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell. 2010 Apr 2;141(1):129-41. | ||||
REF 33 | MiR-20a-5p mediates hypoxia-induced autophagy by targeting ATG16L1 in ischemic kidney injury.Life Sci. 2015 Sep 1;136:133-41. | ||||
REF 34 | miR-103 inhibits proliferation and sensitizes hemopoietic tumor cells for glucocorticoid-induced apoptosis. Oncotarget. 2017 Jan 3;8(1):472-489. | ||||
REF 35 | miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines.Acta Biochim Biophys Sin (Shanghai). 2011 Mar;43(3):217-25. | ||||
REF 36 | MiRNA-20a promotes osteogenic differentiation of human mesenchymal stem cells by co-regulating BMP signaling. RNA Biol. 2011 Sep-Oct;8(5):829-38. | ||||
REF 37 | miR-20a represses endothelial cell migration by targeting MKK3 and inhibiting p38 MAP kinase activation in response to VEGF.Angiogenesis. 2012 Dec;15(4):593-608. | ||||
REF 38 | Hypoxia-induced microRNA-20a expression increases ERK phosphorylation and angiogenic gene expression in endometriotic stromal cells.J Clin Endocrinol Metab. 2012 Aug;97(8):E1515-23. | ||||
REF 39 | Involvement of miR-20a in promoting gastric cancer progression by targeting early growth response 2 (EGR2).Int J Mol Sci. 2013 Aug 6;14(8):16226-39. | ||||
REF 40 | MicroRNA-20a inhibits stress-induced cardiomyocyte apoptosis involving its novel target Egln3/PHD3.J Mol Cell Cardiol. 2012 Mar;52(3):711-7. | ||||
REF 41 | MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours. Br J Cancer. 2013 Sep 17;109(6):1625-35. | ||||
REF 42 | F-box protein FBXO31 is down-regulated in gastric cancer and negatively regulated by miR-17 and miR-20a.Oncotarget. 2014 Aug 15;5(15):6178-90. | ||||
REF 43 | MicroRNAs MiR-17, MiR-20a, and MiR-106b act in concert to modulate E2F activity on cell cycle arrest during neuronal lineage differentiation of USSC. PLoS One. 2011 Jan 20;6(1):e16138. | ||||
REF 44 | The miR-17 2 cluster contributes to MLL leukemia through the repression of MEIS1 competitor PKNOX1.Leuk Res. 2016 Jul;46:51-60. | ||||
REF 45 | Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia. Haematologica. 2011 Dec;96(12):1783-91. | ||||
REF 46 | Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2.Oncogene. 2015 Mar 12;34(11):1407-19. | ||||
REF 47 | Down-regulation of miR-17 family expression in response to retinoic acid induced neuronal differentiation. Cell Signal. 2009 Dec;21(12):1837-45. | ||||
REF 48 | MicroRNA-20a-5p promotes colorectal cancer invasion and metastasis by downregulating Smad4.Oncotarget. 2016 Jul 19;7(29):45199-45213. | ||||
REF 49 | DNA methylation and histone H3-K9 modifications contribute to MUC17 expression.Glycobiology. 2011 Feb;21(2):247-56. | ||||
REF 50 | MiR-17-92 cluster promotes hepatocarcinogenesis. Carcinogenesis. 2015 Oct;36(10):1213-22. | ||||
REF 51 | miR-20a enhances cisplatin resistance of human gastric cancer cell line by targeting NFKBIB.Tumour Biol. 2016 Jan;37(1):1261-9. | ||||
REF 52 | The miRNA-17 2 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation.Leukemia. 2012 May;26(5):1064-72. | ||||
REF 53 | Conditional loss of kidney microRNAs results in congenital anomalies of the kidney and urinary tract (CAKUT).J Mol Med (Berl). 2013 Jun;91(6):739-48. | ||||
REF 54 | Matrix stiffness promotes cartilage endplate chondrocyte calcification in disc degeneration via miR-20a targeting ANKH expression.Sci Rep. 2016 May 4;6:25401. | ||||
REF 55 | MiR-20a and miR-20b negatively regulate autophagy by targeting RB1CC1/FIP200 in breast cancer cells.Life Sci. 2016 Feb 15;147:143-52. | ||||
REF 56 | The miR-20-Rest-Wnt signaling axis regulates neural progenitor cell differentiation.Sci Rep. 2016 Mar 21;6:23300. | ||||
REF 57 | MiR-17-92 represses PTPROt and PP2A phosphatases and amplifies tonic BCR signaling in DLBCL cells.Exp Hematol. 2017 Feb;46:56-61.e1. | ||||
REF 58 | Focal DNA copy number changes in neuroblastoma target MYCN regulated genes.PLoS One. 2013;8(1):e52321. | ||||
REF 59 | Identification of direct targets for the miR-17-92 cluster by proteomic analysis. Proteomics. 2011 Sep;11(17):3531-9. | ||||
REF 60 | MicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation.Nat Cell Biol. 2007 Jul;9(7):775-87. | ||||
REF 61 | HIF-1 downregulates miR-17/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation. Cell Death Differ. 2013 Mar;20(3):408-18. | ||||
REF 62 | Translation of Pur- is targeted by cellular miRNAs to modulate the differentiation-dependent susceptibility of monocytes to HIV-1 infection.FASEB J. 2012 Nov;26(11):4755-64. | ||||
REF 63 | miR-17-5p/20a are important markers for gastric cancer and murine double minute 2 participates in their functional regulation. Eur J Cancer. 2013 May;49(8):2010-21. | ||||
REF 64 | MicroRNA-17/20a/106a modulate macrophage inflammatory responses through targeting signal-regulatory protein .J Allergy Clin Immunol. 2013 Aug;132(2):426-36.e8. | ||||
REF 65 | Inhibition of microRNA-17/20a suppresses cell proliferation in gastric cancer by modulating UBE2C expression.Oncol Rep. 2015 May;33(5):2529-36. | ||||
REF 66 | MicroRNA-17/20a impedes migration and invasion via TGF-/ITGB6 pathway in esophageal squamous cell carcinoma. Am J Cancer Res. 2016 Jul 1;6(7):1549-62. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.